T he STOP-NIDDM trial was an international, doubleblind, placebo-controlled randomised study in people with impaired glucose tolerance (IGT). They were treated with an α-glucosidase inhibitor, acarbose, to prevent diabetes; the overall number needed to treat (NNT) was 11.
Introduction
It has recently been stated that we are facing a pandemic rise in the prevalence of people with impaired glucose tolerance (IGT). The estimated figures for 2004 and 2020 are approximately 200 and 400 million people, respectively. 1 Impaired fasting glucose (IFG) and IGT are high-risk categories for the development of type 2 diabetes. 2 IFG is an accepted trait of the metabolic syndrome (MetS) by the National Cholesterol Education Program Third Adult Treatment Panel (NCEP-ATP III 2001) 3 and the International Diabetes Federation (IDF 2005) 4 definitions. Traits of the MetS independently predict a higher risk for diabetes in individuals with normal glucose tolerance, but in combination, exhibit no higher risk than the sum of risk by single traits. 5 Epidemiological observations have shown that IGT is associated with the MetS according to the NCEP-ATP III or World Health Organization (WHO) definition in about 50% of individuals. 6, 7 Not surprisingly, the presence of MetS has been shown to predict future diabetes, [8] [9] [10] particularly if it includes IFG. In an American Heart Association (AHA) statement, the risk for diabetes and cardiovascular disease (CVD) in representative populations associated with MetS was estimated to reach an odds ratio (OR) of 4 and 2, respectively. 11 We have little information so far from multinational prospective studies in subjects with IGT and the MetS about its individual traits as predictors of diabetes. This question, however, is of clinical relevance since it may allow identification of individuals who are at very high risk of developing diabetes.
The STOP-NIDDM trial was a multinational placebocontrolled randomised prospective study with acarbose in Caucasians with IGT. Acarbose is an α-glucosidase inhibitor which specifically acts on postprandial (pp) hyperglycaemia. 12 This primary prevention trial demonstrated that control of pp hyperglycaemia by acarbose was effective in preventing or delaying type 2 diabetes 13 and possibly CVD morbidity. 14 All variables included in the MetS as defined by NCEP-ATP III criteria were measured at baseline and a standardised 75 g oral glucose tolerance test (OGTT) was carried out. Thus, we were able to evaluate the predictive power of individual components of the MetS according to the NCEP-ATP III definition for the development of diabetes. We also investigated whether the benefits of acarbose treatment on the development of diabetes were related to patients' MetS status.
Research design and methods
Recruitment and study design of the original STOP-NIDDM trial have already been described in detail. Briefly, 1,429 eligible people with IGT and fasting plasma glucose (FPG) > 5.6 mmol/L and < 7.8 mmol/L out of 14,472 screened by 75 g OGTT, aged 40-70 years with a BMI of 25-40 kg/m 2 , were randomly allocated to acarbose (100 mg t.i.d) or placebo and followed for an average of 3.3 years. All accepted traits of the metabolic syndrome were measured at baseline, together with a battery of demographic variables and other risk factors. To enhance the risk for diabetes, participants had to have a FPG at enrolment > 5.6 mmol/L. Thus, all probands had IFG by the IDF definition. 4 Therefore, to evaluate the contribution of IFG to diabetes risk we used the NCEP-ATP III 2001 definition. 3 The five thresholds were: FPG > 6.1 mmol/L, triglycerides > 1.7 mmol/L, low highdensity (HDL)-cholesterol < 1.04 (M) / < 1.29 (F) mmol/L, waist circumference > 102 (M) / > 88 (F) cm and blood pressure > 130/85 mmHg or an antihypertensive medication. Diabetes was diagnosed as a 2-hour post-challenge PG > 11.1 mmol/L based on one OGTT, which was performed yearly. If the FPG was > 7.0 mmol/L during the 3-monthly follow-up visit, the patient was automatically scheduled for an OGTT. Details of recruitment and laboratory analysis have been described previously. 13 
Statistics
Data analysis was performed by SAS Version 8.2 software. Comparison of baseline characteristics was done using t-tests for continuous variables and chi-squared tests for categorical variables. The adjusted hazard ratios for single traits were estimated by applying a stratified (by geographic region) Cox Proportional Hazard model, with treatment group and single or combined traits as covariates. For the multivariate analysis, a selected set of baseline variables was tested in a univariate analysis and included in the multivariate analysis (forward selection, entry level of 5%) along with treatment group and metabolic syndrome if the corresponding p-value was below 0.25 in the univariate model.
Results
A total of 1,368 subjects were available for the intention-totreat (ITT) analysis, of whom 506 developed diabetes (table  1) .
Age and sex distribution were not significantly different between those with and without subsequent development of diabetes. The same applies for blood pressure, levels of low-density lipoprotein (LDL)-cholesterol and smoking. However, BMI, glucose levels, glycosylated haemoglobin (HbA 1C ), fasting and 2-hour post-challenge insulin, homeo-stasis model insulin resistance (HOMA-IR), triglycerides and leucocyte count were significantly higher for patients who developed diabetes, whereas HDL-cholesterol was significantly lower. Patients who progressed to diabetes during the study period were taking more antihypertensive and lipidlowering drugs at enrolment. Prevalence of MetS was significantly higher for MetS by WHO, 15 NCEP-ATP III and IDF definitions in patients with subsequent development of diabetes. Abdominal obesity was the most frequent trait (68%), followed by elevated blood pressure (58%), IFG (55%), hypertriglyceridaemia (52%) and low levels of HDL-cholesterol (50%). Overall, metabolic syndrome by the NCEP-ATP III definition was present in 61% of the patients.
The hazard ratios (HR) for single traits, combinations of traits and overall MetS are given in table 2. IFG, elevated triglycerides, low levels of HDL-cholesterol and elevated blood pressure as single traits are significant predictors of conversion to diabetes. Ranking reveals IGT, with an HR of 1.51, to be the strongest predictor followed by low HDL/hypertriglyceridaemia. Only central obesity does not reach significance as a predictor of conversion to diabetes.
All combinations of two risk factors are associated with a highly significantly increased HR, leading to an overall HR of 1.84 for dual combinations. All the clusters of MetS risk factors significantly increase the risk of diabetes, but the hazard ratios are in the same range as those for dual combinations. Overall MetS was associated with an HR of 1.61 (CI 1.32-1.95, p<0.0001).
In a second step, we analysed the significance of overall MetS and treatment group as categorical variables, together with the parameters for traits and major established risk factors for diabetes as continuous variables, in a proportional hazards model (table 3) .
Multivariate analysis with diabetes as the dependent variable revealed only treatment group, fasting and post-chal-lenge plasma glucose, HbA 1C , triglycerides and WBC count as independent predictors.
As shown in figure 1, in the placebo group patients with MetS had a higher incidence of diabetes than those without MetS. The same applies for the subset with MetS in the acarbose group. Individuals with MetS who were treated with acarbose seem to have the same risk as people in the placebo group without MetS. The lowest incidence of diabetes was found for people without MetS if treated with acarbose. The yearly incidence of diabetes for people with MetS in the placebo group was 18.7%, compared to 11.2% in people without MetS. In the acarbose group 13.5% with MetS and 9.4% without MetS developed diabetes. This resulted in a number needed to treat (NNT) of 5.8 in patients with MetS and 16.5 without MetS to prevent one case of diabetes during the follow-up time of 3.3 years.
Discussion
This secondary analysis of the STOP-NIDDM trial provides further evidence that the MetS is a common finding in people with IGT and FPG > 5.6 mmol/L. We observed a ORIGINAL ARTICLE
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DIABETES AND VASCULAR DISEASE RESEARCH clustering of traits of MetS, e.g. abdominal obesity in 68%, elevated blood pressure in 58%, IFG in 55% and dyslipidaemia in 51%, as has already been shown in secondary analyses of the Diabetes Prevention Trial 7 (DPP) and the Finnish Prevention Study (DPS). 16 In addition, individuals who subsequently developed diabetes had significantly higher levels of insulin resistance and of white blood cells. In our multinational study in Caucasians, the prevalence of overall MetS was 61%. In comparison, the prevalence of MetS in the DPP with a representative sample of the US population was 53%; here, the fasting plasma glucose requirement was > 5.3 mmol/L at baseline. 7 In the DPS, the prevalence of MetS in the baseline was 74% while the fasting plasma glucose level at entry was 6.1 mmol/L. 16 The prevalence of MetS in the STOP-NIDDM trial is intermediate between those with normal glucose tolerance 17 and patients with type 2 diabetes of the same age 18, 19 in Caucasian populations. For example, in the West of Scotland (WOSCOPS) study in moderately hypercholesteraemic men without diabetes, the prevalence of the MetS according to NCEP-ATP III criteria was 26.2%. 20 Since our study excluded patients with FPG < 5.6 mmol/L, the prevalence data are not representative of an unselected population with IGT but present an 'enriched' subgroup with a higher percentage of people with combined hyperglycaemia, as was the case in the DPS. In a representative population of type 2 diabetes -the Diabetes In Germany (DIG) study -74.5% had MetS by the NCEP-ATP III definition. 18 In our analysis of people with IGT, in univariate analysis only IFG, low HDL/hypertriglyceridaemia and elevated blood pressure as single traits carry a higher risk of developing diabetes. In a prospective study in Mauritius investigating subjects with normal glucose tolerance at baseline, all features of the metabolic syndrome were related to a higher risk for development of IGT or diabetes. 5 By contrast, in the present study abdominal obesity was not associated with increased risk for diabetes, either as a categorical or as a continuous variable. In accordance with this finding, in a sevenyear follow-up analysis of the Framingham Offspring Study, large waist circumference was not a significant predictor of diabetes in middle-aged adults. 21 Dual combinations in our study carried a similar risk as people with IFG as the only trait. The same applies for all triple clusters of the MetS. NCEP-ATP III-defined MetS was associated with a 61% increase of risk for development of diabetes, in the same range as risk for single traits and for all dual traits. In the San Antonio Heart Study, it could be shown that MetS predicts diabetes beyond IGT alone. 22 In multivariate analysis, the STOP-NIDDM database analysis using MetS as the categorical variable and all other established risk factors for diabetes as continuous variables found that only FPG, 2-hour PG, HbA 1C , triglycerides and white blood cell count together with treatment were predictors of diabetes, but overall MetS was not. Interestingly, white blood cell count was a strong independent predictor of diabetes. This is consistent with data from the IRAS study 23 and NHANES survey. 24 The importance of leucocyte count as a risk factor for diabetes and CVD has been shown in other prospective studies. 25 As previously published, treatment with acarbose resulted in a reduction in newly diagnosed diabetes of 25%, or 36.1% 13 if the same criteria were applied for diagnosis as in the DPP 26 or DPS, 27 resulting in an overall NNT of 11 for the study duration.
This secondary analysis of the STOP-NIDDM database shows that controlling pp hyperglycaemia with the α-glucosidase inhibitor acarbose is effective in subjects both with and without the metabolic syndrome. However, in people with IGT and MetS, treatment with acarbose reduces the incidence of newly diagnosed diabetes (yearly incidence 13.5%) to levels very close to those of the subset without MetS on placebo (yearly incidence 11.2%). The absolute benefit of acarbose therefore, is distinctly higher in patients with MetS, with a NNT of 5.8 in this group compared to a NNT of 16.5 among those without MetS. Thus, the efficacy of acarbose in patients with MetS was near to that found in prospective trials using lifestyle intervention. For example, the NNT for lifestyle intervention in the DPP was 6.9 27 and in the DPS was 7. 13 As shown in a meta-analysis of long-term trials in patients with type 2 diabetes, acarbose has beneficial effects on three components of MetS: obesity, hypertension and hypertriglyceridaemia. 28 In the STOP-NIDDM trial, a significant reduction of body weight, triglycerides and blood pressure was observed in the patients treated with acarbose. 13, 14 This may be one explanation why acarbose was particularly effective in patients with MetS. According to a recent review by Buchanan on perspectives in diabetes prevention, an integrated approach to the various components of the MetS is needed to improve efficacy of prevention. 29 Our study has several strengths. The database recorded all the components of the metabolic syndrome together with OGTT findings and the classical risk factors for diabetes and CVD. We were able to analyse a rather homogenous but multinational population with 99% Caucasians. The quality of the data and the completeness of events during follow-up have been scrutinised by Cochrane panellists. 30 However, this analysis has also some limitations. First, the study excluded individuals with FPG < 5.6 mmol/L, thus selecting a population with increased risk for diabetes. Finally, it represents a post hoc analysis after the definitions of MetS components were changed.
In conclusion, single components as well as overall MetS label a very high-risk group for diabetes in people with IGT. Acarbose was particularly effective in the prevention of diabetes in patients with MetS, with a number needed to treat of 5.8 vs. 16.5 for patients without MetS.
